MHRA Finalises NIMP Guidance: Compliance Critical for UK Clinical Trial Sponsors by April 2026

London, United Kingdom — 28 April 2026

The Medicines and Healthcare products Regulatory Agency (MHRA) has formally enacted its updated guidance on the use of Non-Investigational Medicinal Products (NIMPs) in clinical trials, effective 28 April 2026. This guidance, accompanying the amended Medicines for Human Use (Clinical Trials) Regulations 2004, clarifies definitions and compliance requirements for all products used within a trial that are not the primary Investigational Medicinal Product (IMP). The changes extend to both medicinal and non-medicinal products, broadening the regulatory oversight for sponsors and investigators.

Under the revised regulations, a NIMP is defined as a medicinal product utilised in a clinical trial as described in the protocol, but not as an IMP. The MHRA mandates that NIMPs should, in most cases, hold a marketing authorisation. If an authorised NIMP is unavailable or its use is commercially unreasonable, an unauthorised NIMP may be employed, contingent upon explicit justification within the trial protocol. Acceptable justifications include product availability issues, excluding price, or preparation according to a magistral or official formula. This stringent requirement directly impacts procurement and formulation strategies, particularly for bespoke trial designs or niche health indications where existing authorised products are scarce.

Categories of NIMPs now specifically addressed include rescue medications, challenge agents, products used to assess endpoints, and background treatments. Rescue medications, integral for participant safety (e.g., managing adverse reactions or failed IMP efficacy), must be clearly outlined. Challenge agents, often non-medicinal products, are used to elicit physiological responses necessary for IMP assessment; their classification as medicinal or non-medicinal dictates specific compliance pathways under the Human Medicines Regulations 2012. Similarly, products used solely to measure trial endpoints, such as PET radiopharmaceuticals, fall under NIMP purview. Background treatments—standard of care medicines administered alongside the IMP—also require careful consideration, particularly when they inform the trial hypothesis.

The guidance explicitly states that investigators and sponsors must be fully aware of this information and act accordingly to achieve and maintain regulatory compliance. This places a direct onus on contract research organisations (CROs) and internal R&D departments to review all ongoing and planned UK-based clinical trials for NIMP compliance ahead of audit.

What this means for United Kingdom

UK supplement manufacturers and brand owners engaged in clinical research must immediately review all trial protocols for NIMP compliance, particularly concerning amendments to the Clinical Trials Regulations 2004, effective 28 April 2026. The requirement for explicit justification for unauthorised NIMPs will increase due diligence costs and potentially extend reformulation windows if existing products lack marketing authorisations or valid justifications. Procurement teams will face tighter constraints on sourcing as the MHRA clarifies medicinal product definitions, impacting ingredient selection for substances previously considered 'non-medicinal'. This regulatory shift also opens avenues for strategic competitive positioning for brands able to demonstrate robust compliance and transparency in their NIMP selection, potentially attracting more research partnerships and enhancing product credibility in a tightening regulatory environment.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.